Mylan’s Bid to Escape EpiPen-Price Antitrust Case Gets Rejected

Mylan NV must continue to defend against litigation accusing it of colluding to inflate the price of life-saving EpiPen injections.

Judge Daniel D. Crabtree of the US District Court for the District of Kansas in a Monday order denied Mylan’s bid for partial judgment on the pleadings, saying the plaintiffs’ complaint plausibly alleged that the company participated in a reverse payment to delay the launch of a cheaper generic version of the EpiPen.

The ruling is a setback for Mylan, which has been trying for years to shake off claims in a wide-ranging dispute over the increasing price of the ...